{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:24:23Z","timestamp":1778768663222,"version":"3.51.4"},"reference-count":132,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cardiacep.theclinics.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiac Electrophysiology Clinics"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.ccep.2015.08.001","type":"journal-article","created":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T19:02:25Z","timestamp":1448305345000},"page":"557-575","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Understanding Heart Failure"],"prefix":"10.1016","volume":"7","author":[{"given":"Jeremy A.","family":"Mazurek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariell","family":"Jessup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccep.2015.08.001_bib1","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the united states: a policy statement from the American Heart Association","volume":"6","author":"Heidenreich","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ccep.2015.08.001_bib2","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib3","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs033","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ccep.2015.08.001_bib4","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1161\/CIRCULATIONAHA.104.500546","article-title":"Mechanisms and models in heart failure: the biomechanical model and beyond","volume":"111","author":"Mann","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ccep.2015.08.001_bib5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib6","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2014.08.036","article-title":"Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction","volume":"64","author":"Mentz","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1161\/CIRCULATIONAHA.111.080770","article-title":"Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes","volume":"126","author":"Steinberg","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ccep.2015.08.001_bib8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cardfail.2014.05.003","article-title":"Outcomes in world health organization group II pulmonary hypertension: mortality and readmission trends with systolic and preserved ejection fraction-induced pulmonary hypertension","volume":"20","author":"Salamon","year":"2014","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.ccep.2015.08.001_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nrd2219","article-title":"Drug discovery for heart failure: a new era or the end of the pipeline?","volume":"6","author":"Kaye","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ccep.2015.08.001_bib10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjcard.2006.01.059","article-title":"Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease","volume":"98","author":"Ferrario","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib11","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.amjcard.2009.01.013","article-title":"Effects of left ventricular volume overload on mitochondrial and death-receptor-mediated apoptotic pathways in the transition to heart failure","volume":"103","author":"Moorjani","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib12","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1161\/01.CIR.0000129318.79570.84","article-title":"Relations of plasma matrix metalloproteinase-9 to\u00a0clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study","volume":"109","author":"Sundstrom","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ccep.2015.08.001_bib13","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/01.CIR.85.2.790","article-title":"Adrenergic effects on the biology of the adult mammalian cardiocyte","volume":"85","author":"Mann","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.ccep.2015.08.001_bib14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/07853890510007232","article-title":"Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications","volume":"37","author":"Aukrust","year":"2005","journal-title":"Ann Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib15","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1056\/NEJMra021498","article-title":"Heart failure","volume":"348","author":"Jessup","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib16","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1161\/CIRCULATIONAHA.106.174287","volume":"113","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ccep.2015.08.001_bib17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12350-008-9010-8","article-title":"Etiology and pathophysiology of new-onset heart failure: evaluation by myocardial perfusion imaging","volume":"16","author":"Soman","year":"2009","journal-title":"J\u00a0Nucl Cardiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib18","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1093\/eurheartj\/ehn072","article-title":"Non-invasive diagnosis of ischaemic heart failure using 64-slice computed tomography","volume":"29","author":"Ghostine","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ccep.2015.08.001_bib19","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/HCO.0000000000000160","article-title":"Genetics of common forms of heart failure: challenges and potential solutions","volume":"30","author":"Rau","year":"2015","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib20","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.jacc.2011.01.015","article-title":"Update 2011: clinical and genetic issues in familial dilated cardiomyopathy","volume":"57","author":"Hershberger","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib21","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.amjcard.2011.06.022","article-title":"Review and metaanalysis of the frequency of familial dilated cardiomyopathy","volume":"108","author":"Petretta","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib22","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/j.jacc.2013.08.1644","article-title":"The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation","volume":"62","author":"Arbustini","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib23","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jacc.2014.05.027","article-title":"The MOGE(S) classification of cardiomyopathy for clinicians","volume":"64","author":"Arbustini","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1053\/j.seminoncol.2013.01.005","article-title":"Asymptomatic cardiac toxicity in long-term cancer survivors: defining the population and recommendations for surveillance","volume":"40","author":"Carver","year":"2013","journal-title":"Semin Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.ccep.2015.08.001_bib25","doi-asserted-by":"crossref","first-page":"v277","DOI":"10.1093\/annonc\/mdq200","article-title":"Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO clinical practice guidelines","volume":"21","author":"Bovelli","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ccep.2015.08.001_bib26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cardfail.2014.11.008","article-title":"Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma","volume":"21","author":"Grandin","year":"2015","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.ccep.2015.08.001_bib27","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa020245","article-title":"Obesity and the risk of heart failure","volume":"347","author":"Kenchaiah","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib28","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.2337\/diacare.27.8.1879","article-title":"The incidence of congestive heart failure in type 2 diabetes: an update","volume":"27","author":"Nichols","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ccep.2015.08.001_bib29","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0002-9149(97)89163-1","article-title":"Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry","volume":"77","author":"Shindler","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00000441-200104000-00003","article-title":"Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome","volume":"321","author":"Alpert","year":"2001","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.ccep.2015.08.001_bib31","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1194\/jlr.P900032-JLR200","article-title":"Myocardial lipid accumulation in patients with pressure-overloaded heart and metabolic syndrome","volume":"50","author":"Marfella","year":"2009","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.ccep.2015.08.001_bib32","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1194\/jlr.R001115","article-title":"Myocardial lipid accumulation and lipotoxicity in heart failure","volume":"50","author":"Schulze","year":"2009","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.ccep.2015.08.001_bib33","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1007\/s00125-004-1572-7","article-title":"Antioxidative treatment prevents activation of death-receptor- and mitochondrion-dependent apoptosis in the hearts of diabetic rats","volume":"47","author":"Bojunga","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.ccep.2015.08.001_bib34","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1161\/01.CIR.97.17.1695","article-title":"Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in\u00a0vivo","volume":"97","author":"Williams","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ccep.2015.08.001_bib35","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11906-007-0086-3","article-title":"Diabetic cardiomyopathy","volume":"9","author":"Karnik","year":"2007","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.ccep.2015.08.001_bib36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.107.728550","article-title":"Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension","volume":"117","author":"van Heerebeek","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ccep.2015.08.001_bib37","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.106.621854","article-title":"Advanced glycation end products: sparking the development of diabetic vascular injury","volume":"114","author":"Goldin","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ccep.2015.08.001_bib38","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/clc.20456","article-title":"Glucagon-like peptide-1 and myocardial protection: more than glycemic control","volume":"32","author":"Fields","year":"2009","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib39","series-title":"Nomenclature and criteria for diagnosis of diseases of the heart and great vessels","first-page":"253","author":"The Criteria Committee of the New York Heart Association","year":"1994"},{"key":"10.1016\/j.ccep.2015.08.001_bib40","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1161\/hc4901.102568","volume":"104","author":"Hunt","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ccep.2015.08.001_bib41","first-page":"1429","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS trial study group","volume":"316","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib42","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators","volume":"325","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib43","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD investigators","volume":"327","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib44","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib45","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.mcna.2012.07.010","article-title":"Evidence-based therapy for heart failure","volume":"96","author":"Deedwania","year":"2012","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.ccep.2015.08.001_bib46","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ccep.2015.08.001_bib47","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib48","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A\u00a0randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib49","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ccep.2015.08.001_bib50","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib51","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0002-9149(01)02261-5","article-title":"Relation of aldosterone \u201cescape\u201d despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy","volume":"89","author":"Cicoira","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib52","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib53","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib54","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group","volume":"334","author":"Packer","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib55","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ccep.2015.08.001_bib56","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ccep.2015.08.001_bib57","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib58","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol european trial (COMET): randomised controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ccep.2015.08.001_bib59","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJM200105313442202","article-title":"Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure","volume":"344","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib60","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ccep.2015.08.001_bib61","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.jacc.2012.01.020","article-title":"Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial) study","volume":"59","author":"Swedberg","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib62","unstructured":"FDA news release: FDA approves corlanor to treat heart failure. 2015. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm442978.htm. Accessed April 30, 2015."},{"key":"10.1016\/j.ccep.2015.08.001_bib63","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study","volume":"314","author":"Cohn","year":"1986","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib64","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A\u00a0comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure","volume":"325","author":"Cohn","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib65","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S1071-9164(99)90001-5","article-title":"Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group","volume":"5","author":"Carson","year":"1999","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.ccep.2015.08.001_bib66","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJM200105033441802","article-title":"Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction","volume":"344","author":"Exner","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib67","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib68","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","author":"Digitalis Investigation Group","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib69","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jama.289.7.871","article-title":"Association of serum digoxin concentration and outcomes in patients with heart failure","volume":"289","author":"Rathore","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ccep.2015.08.001_bib70","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jacc.2014.01.051","article-title":"The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions","volume":"63","author":"Ambrosy","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib71","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1056\/NEJMoa021266","article-title":"Sex-based differences in the effect of digoxin for the treatment of heart failure","volume":"347","author":"Rathore","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib72","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJM199612263352601","article-title":"Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter automatic defibrillator implantation trial investigators","volume":"335","author":"Moss","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib73","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib74","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib75","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJM199711273372202","article-title":"A\u00a0comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators","volume":"337","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib76","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.jacc.2012.12.014","volume":"61","author":"Epstein","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib77","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jacc.2007.09.073","article-title":"Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact","volume":"51","author":"Daubert","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib78","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.jacc.2012.02.036","article-title":"Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator","volume":"59","author":"Barsheshet","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib79","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1056\/NEJMoa0901889","article-title":"Defibrillator implantation early after myocardial infarction","volume":"361","author":"Steinbeck","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib80","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa041489","article-title":"Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction","volume":"351","author":"Hohnloser","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib81","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2010.1915","article-title":"Non-evidence-based ICD implantations in the United States","volume":"305","author":"Al-Khatib","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ccep.2015.08.001_bib82","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1503\/cmaj.080769","article-title":"Maximum potential benefit of implantable defibrillators in preventing sudden death after hospital admission because of heart failure","volume":"180","author":"Setoguchi","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.ccep.2015.08.001_bib83","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.hrthm.2009.04.010","article-title":"Implantable cardioverter-defibrillator prescription in the elderly","volume":"6","author":"Epstein","year":"2009","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.ccep.2015.08.001_bib84","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-153-9-201011020-00009","article-title":"Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators","volume":"153","author":"Santangeli","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib85","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCEP.108.777888","article-title":"Patient and implanting physician factors associated with mortality and complications after implantable cardioverter-defibrillator implantation, 2002-2005","volume":"1","author":"Al-Khatib","year":"2008","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib86","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1161\/hc4201.097134","article-title":"Ionic remodeling of cardiac purkinje cells by congestive heart failure","volume":"104","author":"Han","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ccep.2015.08.001_bib87","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ehj.2003.09.030","article-title":"Interventricular and intraventricular dyssynchrony are common in heart failure patients, regardless of QRS duration","volume":"25","author":"Ghio","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ccep.2015.08.001_bib88","doi-asserted-by":"crossref","first-page":"H2238","DOI":"10.1152\/ajpheart.00684.2001","article-title":"Left ventricular resynchronization therapy in a canine model of left bundle branch block","volume":"282","author":"Liu","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib89","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1056\/NEJM200103223441202","article-title":"Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay","volume":"344","author":"Cazeau","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib90","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa013168","article-title":"Cardiac resynchronization in chronic heart failure","volume":"346","author":"Abraham","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib91","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa032423","article-title":"Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure","volume":"350","author":"Bristow","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib92","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":"The effect of cardiac resynchronization on morbidity and mortality in heart failure","volume":"352","author":"Cleland","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib93","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/j.jacc.2008.08.027","article-title":"Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms","volume":"52","author":"Linde","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib94","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","article-title":"Cardiac-resynchronization therapy for the prevention of heart-failure events","volume":"361","author":"Moss","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib95","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1009540","article-title":"Cardiac-resynchronization therapy for mild-to-moderate heart failure","volume":"363","author":"Tang","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib96","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.jacc.2009.08.011","volume":"54","author":"Daubert","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib97","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1161\/CIRCULATIONAHA.108.818724","article-title":"Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I\/II heart failure","volume":"120","author":"St John Sutton","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ccep.2015.08.001_bib98","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.hfc.2014.12.007","article-title":"Cardiac resynchronization therapy: past, present, and future","volume":"11","author":"Chatterjee","year":"2015","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.ccep.2015.08.001_bib99","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1161\/CIRCRESAHA.113.300270","article-title":"Electromechanical dyssynchrony and resynchronization of the failing heart","volume":"113","author":"Kirk","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.ccep.2015.08.001_bib100","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1001\/archinternmed.2011.247","article-title":"Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials","volume":"171","author":"Sipahi","year":"2011","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib101","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ahj.2011.11.014","article-title":"Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials","volume":"163","author":"Sipahi","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.ccep.2015.08.001_bib102","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1161\/CIRCULATIONAHA.112.097709","article-title":"Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the resynchronization reverses remodeling in systolic left ventricular dysfunction (REVERSE) study","volume":"126","author":"Gold","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ccep.2015.08.001_bib103","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.jacc.2012.01.065","article-title":"Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study","volume":"59","author":"Hsu","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib104","series-title":"Multicenter automatic defibrillator implantation trial - chemotherapy-induced cardiomyopathy (MADIT-CHIC)","author":"University of Rochester","year":"2000"},{"key":"10.1016\/j.ccep.2015.08.001_bib105","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ahj.2007.10.020","article-title":"Characteristics of \u201cstage D\u201d heart failure: insights from the Acute Decompensated Heart Failure National Registry Longitudinal Module (ADHERE LM)","volume":"155","author":"Costanzo","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.ccep.2015.08.001_bib106","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ejheart.2007.04.003","article-title":"Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology","volume":"9","author":"Metra","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ccep.2015.08.001_bib107","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/CIRCULATIONAHA.111.060830","article-title":"Mechanical circulatory support for advanced heart failure: patients and technology in evolution","volume":"125","author":"Stewart","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ccep.2015.08.001_bib108","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJMoa012175","article-title":"Long-term use of a left ventricular assist device for end-stage heart failure","volume":"345","author":"Rose","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib109","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMoa0909938","article-title":"Advanced heart failure treated with continuous-flow left ventricular assist device","volume":"361","author":"Slaughter","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib110","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa067758","article-title":"Use of a continuous-flow device in patients awaiting heart transplantation","volume":"357","author":"Miller","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib111","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1161\/CIRCULATIONAHA.111.058412","article-title":"Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation","volume":"125","author":"Aaronson","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ccep.2015.08.001_bib112","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.healun.2014.04.010","article-title":"Sixth INTERMACS annual report: a 10,000-patient database","volume":"33","author":"Kirklin","year":"2014","journal-title":"J\u00a0Heart Lung Transpl"},{"key":"10.1016\/j.ccep.2015.08.001_bib113","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1313385","article-title":"Unexpected abrupt increase in left ventricular assist device thrombosis","volume":"370","author":"Starling","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib114","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMra0800239","article-title":"Biomarkers in heart failure","volume":"358","author":"Braunwald","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib115","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jacc.2013.07.087","article-title":"Head-to-head comparison of two myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 vs. galectin-3","volume":"63","author":"Bayes-Genis","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib116","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jacc.2012.12.044","article-title":"B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction","volume":"61","author":"van Veldhuisen","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib117","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccep.2015.08.001_bib118","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","article-title":"Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial","volume":"381","author":"Teerlink","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ccep.2015.08.001_bib119","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0140-6736(11)61126-4","article-title":"The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial","volume":"378","author":"Cleland","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ccep.2015.08.001_bib120","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.cardfail.2013.04.002","article-title":"Acute decompensated heart failure: update on new and emerging evidence and directions for future research","volume":"19","author":"Givertz","year":"2013","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.ccep.2015.08.001_bib121","series-title":"Efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients with preserved ejection fraction (PARAGON-HF)","author":"Novartis Pharmaceuticals","year":"2000"},{"key":"10.1016\/j.ccep.2015.08.001_bib122","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jacc.2007.10.061","article-title":"Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study","volume":"51","author":"Bourge","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib123","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0140-6736(11)60101-3","article-title":"Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial","volume":"377","author":"Abraham","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ccep.2015.08.001_bib124","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jchf.2014.05.007","article-title":"Rationale and design of the GUIDE-IT study: guiding evidence based therapy using biomarker intensified treatment in heart failure","volume":"2","author":"Felker","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ccep.2015.08.001_bib125","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/clpt.2011.187","article-title":"The impact of pharmacogenomics on the management of cardiac disease","volume":"90","author":"Pereira","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ccep.2015.08.001_bib126","doi-asserted-by":"crossref","first-page":"11288","DOI":"10.1073\/pnas.0509937103","article-title":"A\u00a0polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure","volume":"103","author":"Liggett","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ccep.2015.08.001_bib127","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/europace\/eut136","article-title":"Adrenergic receptor gene polymorphism and left ventricular reverse remodelling after cardiac resynchronization therapy: preliminary results","volume":"15","author":"Pezzali","year":"2013","journal-title":"Europace"},{"key":"10.1016\/j.ccep.2015.08.001_bib128","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jacc.2013.11.031","article-title":"Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data","volume":"63","author":"Damman","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccep.2015.08.001_bib129","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.hfc.2014.12.006","article-title":"Stem cell therapy for heart failure","volume":"11","author":"Patel","year":"2015","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.ccep.2015.08.001_bib130","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.hfc.2014.12.008","article-title":"Ablation of atrial arrhythmias in heart failure","volume":"11","author":"Aagaard","year":"2015","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.ccep.2015.08.001_bib131","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jchf.2013.11.002","article-title":"Outcomes of Medicare beneficiaries with heart failure and atrial fibrillation","volume":"2","author":"Khazanie","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ccep.2015.08.001_bib132","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1161\/CIRCHEARTFAILURE.111.966135","article-title":"Heart allocation in the United States: intended and unintended consequences","volume":"5","author":"Givertz","year":"2012","journal-title":"Circ Heart Fail"}],"container-title":["Cardiac Electrophysiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877918215001069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877918215001069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T13:55:11Z","timestamp":1537192511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877918215001069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":132,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1877918215001069"],"URL":"https:\/\/doi.org\/10.1016\/j.ccep.2015.08.001","relation":{},"ISSN":["1877-9182"],"issn-type":[{"value":"1877-9182","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding Heart Failure","name":"articletitle","label":"Article Title"},{"value":"Cardiac Electrophysiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccep.2015.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}